Canine influenza virus (CIV) is an emerging pathogen that causes acute respiratory disease in dogs. As with any communicable disease, dog-to-dog transmission of CIV occurs when infected dogs come in ...contact with other susceptible dogs. We demonstrate that CIV transmission occurs readily from CIV-infected dogs to susceptible dogs following co-mingling. Four experimentally infected dogs were co-mingled with a group of eight CIV-negative dogs at 1 day post-infection and both groups were observed for CIV-associated respiratory disease. The onset of clinical signs, virus shedding, seroconversion, and appearance of lung lesions were observed earlier in experimentally infected dogs; however, the severity of the clinical signs and lung lesions were very similar in both groups. One hundred percent of the experimentally infected dogs and 75% of the contact-exposed dogs excreted virus in their nasal secretions. Additionally, 100% of experimentally infected dogs and 75% of the contact-exposed dogs exhibited varying degrees of pneumonia. Our study results demonstrate that CIV spreads readily from infected dogs to other susceptible dogs through direct contact.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK
Previous studies have demonstrated that nociceptin/orphanin FQ (N/OFQ), the endogenous peptide ligand for the G-protein-coupled NOP receptor, inhibits cough in experimental models. SCH 225288 is a ...nonpeptide, orally active NOP agonist that may provide the foundation for the development of novel treatments for cough.
First we characterized the selectivity of SCH 225288 in human receptor binding assays. Afterwards, the antitussive activity of SCH 225288 was studied in three mechanistically distinct cough models. Specifically, we observed the cough-suppressant effect of SCH 225288 in a guinea pig capsaicin irritant-evoked cough model, a feline mechanically induced cough model and finally in a canine Bordetella bronchiseptica disease model.
SCH 225288 selectively binds human NOP receptor (K(i) = 0.38 +/- 0.02 nmol/l) over classical opioid receptors (COR). In a guinea pig capsaicin cough model, SCH 225288 (0.1-1 mg/kg) suppressed cough at 2, 4, and 6 h after oral administration. The antitussive effect of SCH 225288 (3.0 mg/kg, p.o.) was blocked by the NOP antagonist J113397 (12 mg/kg, i.p.) but not by the classical opioid receptor (COR) antagonist, naltrexone (3.0 mg/kg, i.p.). In the anesthetized cat, we evaluated the effects of SCH 225288 given either intravenously or via the intravertebral artery against the increases in cough number and respiratory expiratory and inspiratory muscle (rectus abdominis and parasternal) electromyographic (EMG) activities due to perturbations of the intrathoracic trachea. SCH 225288 (0.03-3.0 mg/kg, i.v.) inhibited both cough number and abdominal EMG amplitudes. Similarly, SCH 225288 (0.001-0.3 mg/kg) administered intra-arterially also diminished cough number and abdominal EMG amplitudes. No significant effect of the drug was noted on parasternal EMG activity. Finally, we studied the antitussive actions of SCH 225288 (1.0 mg/kg) in a canine B. bronchiseptica disease model. In this model, dogs were challenged intranasally with B. bronchiseptica. Comparisons were made between a vehicle group, an SCH 225288 (1.0 mg/kg, p.o., q.d.) and a butorphanol (0.6 mg/kg, p.o., b.i.d.) group on the mean change in cough scores from baseline values and days 6-9 after B. bronchiseptica challenge. SCH 225288 (1.0 mg/kg, p.o., q.d.) displayed a positive antitussive tendency (p = 0.06) to inhibit B. bronchiseptica cough whereas butorphanol (0.6 mg/kg, p.o., b.i.d.) was devoid of antitussive activity.
Taken together, the present data show that SCH 225288 is a potent and effective antitussive agent in animal models of cough. Furthermore, these findings indicate that NOP agonists represent a promising new therapeutic approach for the treatment of cough without the side effect liabilities associated with opioid antitussives.
Canine influenza virus (CIV) subtype H3N8 has emerged as a new pathogen with sustained transmission in the dog population in the United States. In this study, we report the experimental induction of ...respiratory disease in dogs using three CIV field isolates. Young (14 to 15 weeks of age) CIV-seronegative pups were challenged with one of three CIV isolates and monitored for clinical signs of respiratory disease, nasal virus shedding, seroconversion, lung lesions, and virus isolation from the lower respiratory tract. The challenged pups developed clinical signs and lung lesions typical of influenza virus infection, shed virus in their nasal secretions for 7 to 8 days after challenge, and exhibited serum antibodies at 7 and 14 days after challenge. Lung tissues and tracheal swabs collected at 3 and 6 days after challenge exhibited active virus replication. These results demonstrate that CIV causes respiratory disease in dogs.
Healthy dogs with low antibody titer to Bordetella bronchiseptica were vaccinated intranasally with an avirulent live vaccine, subcutaneously with an antigen extract vaccine, or subcutaneously and ...intranasally with a placebo. Intranasally vaccinated dogs developed B. bronchiseptica-specific IgA titers in nasal secretions that remained at high levels until the end of the study; dogs vaccinated subcutaneously with the antigen extract or placebo did not develop measurable antigen-specific IgA titers in nasal secretions. Dogs were challenged with virulent live B. bronchiseptica 63 days after vaccination. Intranasally vaccinated dogs had significantly lower cough scores (P < or =.0058) and shed significantly fewer challenge organisms (P <.0001) than dogs in either of the other groups. Cough scores of subcutaneously vaccinated dogs were not significantly different from placebo-vaccinated dogs.
Three groups of healthy dogs with low antibody titers to Bordetella bronchiseptica (Bb), canine parainfluenza virus (CPI), and canine adenovirus type 2 (CAV-2) were used in this study. One group was ...vaccinated with a single dose of monovalent attenuated Bb vaccine and one group with a trivalent vaccine containing attenuated Bb, CPI, and CAV-2; dogs were vaccinated intranasally with a single dose of the respective vaccines. The third group served as unvaccinated controls. All vaccinated dogs subsequently developed serum antibody titers to Bb that persisted for at least 1 year. Following Bb challenge 1 year after vaccination, all vaccinated dogs, regardless of group, showed significantly fewer clinical signs and shed significantly fewer challenge organisms than unvaccinated controls. These results demonstrate that intranasal administration of a single dose of monovalent attenuated Bb vaccine or trivalent vaccine containing attenuated Bb, CPI, and CAV-2 provides 1 year of protection against Bb.
Enterotoxigenic Escherichia coli is one of the primary etiologic agents for diarrhea in neonatal calves. Immunization of dams can provide passive protection in neonatal calves; antibodies transferred ...through colostrum block colonization of bacteria, thereby preventing disease. In this study, healthy pregnant heifers were vaccinated at approximately 3 months of gestation with either a polyvalent oil-adjuvanted vaccine containing inactivated coronavirus, rotavirus, E. coli K99 subunit antigen, and Clostridium perfringens b and e toxoid or normal saline as a placebo. Calves were allowed to nurse immediately after birth, were orally challenged with virulent heterologous enterotoxigenic E. coli at 1 day of age, and were observed for clinical signs of scours for 10 days. Signs of severe scours were noted in 75% of control calves and 28.6% of vaccinates, and the severity of scours was significantly higher (P = .0382) in the control group. The mortality rate was significantly higher (P = .0007) in the control group (80%) than in the vaccinate group (14%). These findings indicate that the vaccination of pregnant heifers at as early as 3 months of gestation (6 months before calving) provides passive protection in neonatal calves against colibacillosis.
Canine influenza virus (CIV) subtype H3N8 is an emerging pathogen with sustained horizontal transmission in the dog population in the United States. This study evaluated the efficacy of an ...inactivated CIV vaccine in 6- to 8-week-old beagle pups challenged with virulent CIV. One group of CIV-seronegative pups was vaccinated with two doses of a CIV vaccine 3 weeks apart; a second group of pups received adjuvanted placebo as a control. Blood samples were collected at various times to determine antibody titers. All pups were challenged with a virulent CIV isolate 13 days after the second vaccination and monitored for clinical signs of respiratory disease, virus shedding, and lung consolidation. Vaccinated pups developed hemagglutination inhibition antibody titers after vaccination. The severity of clinical signs (P < .001) and the magnitude and duration of virus shedding (P < .0001) were significantly lower in vaccinated pups compared with control pups. These results demonstrate that the CIV vaccine used in this study provides protection against virulent CIV challenge in dogs.
PDF
